Lewy bodies composed of aggregates of α-synuclein (αS) in the brain are the main histopathological features of Lewy body diseases (LBD) such as Parkinson's disease and dementia with Lewy bodies. Mutations such as E46K, A30P and A53T in the αS gene cause autosomal dominant LBD in a number of kindreds. Although these mutations accelerate fibril formation, their precise effects at early stages of the αS aggregation process remain unknown. To answer this question, we examined the aggregation including monomer conformational dynamics and oligomerization of the E46K, A30P, A53T and A30P/A53T mutations and wild type (WT) using thioflavin S assay, circular dichroism spectroscopy, photo-induced cross-linking of unmodified proteins, electron microscopy, and atomic force microscopy. Relative to WT αS, E46K αS accelerated the kinetics of the secondary structure change and oligomerization, whereas A30P αS decelerated them. These effects were reflected in changes in average oligomer size. The mutant oligomers of E46K αS functioned as fibril seeds significantly more efficiently than those of WT αS, whereas the mutant oligomers of A30P αS were less efficient. Our results that mutations of familial LBD had opposite effects at early stages of αS assembly may provide new insight into the molecular mechanisms of LBD.
Introduction
Parkinson's disease (PD) is a neurodegenerative movement disorder characterized by the selective loss of dopaminergic neurons from the substantial nigra, and the appearance of intraneuronal inclusions, called Lewy bodies (LBs) and Lewy neurites. LBs are composed of a dense core of fibrillar structures whose major component is α-synuclein (αS) (Baba et al., 1998; Spillantini et al., 1998) . Aggregation of αS is considered to be an important and, probably, seminal step in the development of Lewy body diseases (LBD) including PD and dementia with LBs (DLB) and other α-synucleinopathies such as multiple system atrophy (Ono et al., 2008; Uversky, 2007) .
Genetic studies of the αS gene in familial cases of PD and DLB have demonstrated that expression of abnormal αS or overexpression of normal αS is associated with these diseases. Pathogenic missense mutations [A53T (Polymeropoulos et al., 1997) , A30P (Kruger et al., 1998), and E46K (Zarranz et al., 2004) and multiplication (ChartierHarlin et al., 2004; Farrer et al., 2004; Fuchs et al., 2007; Ibanez et al., 2004; Nishioka et al., 2006; Singleton et al., 2003) ] of the αS gene have been identified in kindreds of autosomal dominantly inherited familial PD and DLB (Fig. 1) .
αS is a 140-amino acid protein, having an N-terminal domain with seven imperfect KTKEGV sequence repeats, followed by a hydrophobic central region (non-amyloid β-protein (Aβ) component of Alzheimer disease (NAC)) and C-terminal domain with a large portion of acidic residues. The repeat region at the N-terminus has been assumed to form an amphipathic α-helix by binding to phospholipid (Davidson et al., 1998) . Circular dichroism and Fourier-transform IR analysis revealed that αS is a natively unfolded protein without a highly ordered secondary structure (Uversky et al., 2001 ). Recent nuclear magnetic resonance (NMR) analyses have revealed three intramolecular long range interactions. These interactions are between the highly hydrophobic NAC region (residues 85-95) and the C terminus (residues 110-130), C-terminal residues 120-130 and residues 105-115, and the region around residue 120 and the N terminus around residue 20 (Bertoncini et al., 2005b; Bussell and Eliezer, 2001; Dedmon et al., 2005) .
Upon incubation at 37°C at a high concentration with agitation, recombinant αS assembles into fibrils that closely resemble those in the PD or DLB brain (Conway et al., 1998 (Conway et al., , 2000a . Assembly of αS into αS fibrils (fαS) follows a nucleation-dependent process that consists of a lag phase (nucleation) and a growth phase (elongation) (Wood et al., 1999) . The prevalence of fαS associated with LBD has led many researchers to hypothesize that they cause cell death (Duda et al., 2000; Spillantini et al., 1998) . However, recent evidence suggests that the earlier intermediates, αS oligomers may be more toxic components (Danzer et al., 2007; Karpinar et al., 2009; Outeiro et al., 2008; Wright et al., 2009) .
αS, which is predominantly non-phosphorylated in vivo under normal conditions (Fujiwara et al., 2002) , is extensively phosphorylated at Ser129 in α-synucleinopathic lesions (Fujiwara et al., 2002; Nishie et al., 2004) . The specific phosphorylation of αS at Ser129 by 
